Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 2
2007 2
2009 1
2010 5
2011 7
2012 8
2013 10
2014 3
2015 7
2016 8
2017 14
2018 7
2019 7
2020 7
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

81 results
Results by year
Filters applied: . Clear all
Page 1
CDK4/6 inhibition triggers anti-tumour immunity.
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. Goel S, et al. Among authors: ma cx. Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16. Nature. 2017. PMID: 28813415 Free PMC article.
PI3K Inhibitors in Breast Cancer Therapy.
Ellis H, Ma CX. Ellis H, et al. Among authors: ma cx. Curr Oncol Rep. 2019 Dec 11;21(12):110. doi: 10.1007/s11912-019-0846-7. Curr Oncol Rep. 2019. PMID: 31828441 Review.
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH; Human Tumor Atlas Network. Rozenblatt-Rosen O, et al. Cell. 2020 Apr 16;181(2):236-249. doi: 10.1016/j.cell.2020.03.053. Cell. 2020. PMID: 32302568 Free article. Review.
NCCN Guidelines Insights: Antiemesis, Version 2.2017.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. Berger MJ, et al. Among authors: ma cx. J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117. J Natl Compr Canc Netw. 2017. PMID: 28687576
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Bose R, et al. Among authors: ma cx. Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7. Cancer Discov. 2013. PMID: 23220880 Free PMC article.
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J, Ma CX. Xi J, et al. Among authors: ma cx. Curr Oncol Rep. 2020 May 16;22(6):57. doi: 10.1007/s11912-020-00917-8. Curr Oncol Rep. 2020. PMID: 32415339 Review.
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ. Ma CX, et al. Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7. Clin Cancer Res. 2017. PMID: 28270497 Free PMC article. Clinical Trial.
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N. Nayar U, et al. Among authors: ma cx. Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10. Nat Genet. 2019. PMID: 30531871
Mechanisms of aromatase inhibitor resistance.
Ma CX, Reinert T, Chmielewska I, Ellis MJ. Ma CX, et al. Nat Rev Cancer. 2015 May;15(5):261-75. doi: 10.1038/nrc3920. Nat Rev Cancer. 2015. PMID: 25907219 Review.
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ. Lei JT, et al. Among authors: ma cx. Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009. Cell Rep. 2018. PMID: 30089255 Free PMC article.
81 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback